Whalesbook
Board Approves Share Allotment
The Board of Directors of Novelix Pharmaceuticals Limited, in a meeting held on March 30, 2026, approved the allotment of 11,50,000 equity shares. These shares were issued at ₹20 each (₹10 face value and ₹10 premium) upon the conversion of warrants. The company received ₹17.25 crore, representing 75% of the issue price paid on the warrants.
This allotment has increased the company's paid-up equity capital from ₹19.94 crore (₹1,99,35,000) to ₹21.09 crore (₹2,10,85,000).
The shares were allotted to strategic investors from the promoter and promoter group categories, including SRINIDHI FINE-CHEMICALS LLP and NARAHARI BELIDE.
Strategic Importance of Capital
This capital infusion strengthens Novelix Pharmaceuticals' financial base, providing funds that can be utilized for operational growth, research initiatives, or working capital needs. It aligns with the company's strategic pivot towards pharmaceutical research, bulk drug manufacturing, and healthcare technology.
Consistent capital raising through warrants and preferential issues indicates a strategy to fund expansion and operations via equity, potentially reducing reliance on debt.
Company's Evolution and Strategy
Novelix Pharmaceuticals, formerly known as Trimurti Limited, has a history of raising capital through various instruments. The company underwent a name change in October 2024 to reflect its focus on the pharmaceutical sector. Its business has evolved from trading securities to specializing in pharmaceutical intermediates, bulk drugs (APIs), and healthcare research.
The warrants for this conversion were part of 15,000,000 warrants originally allotted on January 10, 2025. This allotment followed shareholder approval at an EGM on November 18, 2024, and received in-principle approval from BSE Limited on December 31, 2024. Previous conversions of these warrants have also occurred throughout 2025 and early 2026, demonstrating ongoing capital-raising activities.
Key Changes Post-Allotment
- Increased Equity Base: More outstanding shares could mean earnings dilution per share.
- Strengthened Balance Sheet: The capital infusion improves the company's financial health and cash availability.
- Investor Confidence: Conversion by strategic investors signals confidence in the company's future.
- Capital Deployment: Funds are now available for planned expansion and operations.
Competitive Landscape
Novelix Pharmaceuticals operates within the competitive Indian pharmaceutical landscape. Peers like Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, and Lupin are large, established players with significant R&D investments and global market presence. While these larger peers focus on innovation and broad therapeutic areas, Novelix, as a micro-cap entity, is consolidating its position in bulk drugs and research, leveraging capital raises to fuel its growth strategy.
Key Financial Data
- The company's paid-up equity capital increased from ₹19.94 crore to ₹21.09 crore as of Q4 FY26.
- ₹17.25 crore was received from the conversion of warrants during Q4 FY26.
- In FY25, the company reported net sales of ₹209 crore and a net profit of ₹2 crore.
Investor Focus Points
- Fund Utilization: Monitor how effectively the raised capital is deployed to drive operational growth and meet strategic objectives.
- Financial Performance: Track upcoming quarterly results for signs of improved profitability and efficiency.
- Regulatory Filings: Observe any further capital-raising activities or significant corporate actions.
- Sectoral Trends: Keep an eye on broader trends in the pharmaceutical sector, particularly in bulk drugs and R&D.
- Management Commentary: Analyze concall transcripts for insights into future strategy and fund deployment plans.